Search

Corvus Pharmaceuticals Inc

Uždarymo kaina

15.7 -2.91

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

15.51

Max

15.87

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.4M

-14M

Pelnas, tenkantis vienai akcijai

-0.15

Darbuotojai

37

EBITDA

312K

-12M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+101.66% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-71M

1.3B

Ankstesnė atidarymo kaina

18.61

Ankstesnė uždarymo kaina

15.7

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-12 23:51; UTC

Cryptocurrency market mixed as Bitcoin dips and Ethereum rises ahead of key U.S. inflation data releases impacting Federal Reserve policy.

2026-07-12 23:51; UTC

Markets brace for key U.S. inflation and retail sales data releases, with potential implications for Federal Reserve policy amid ongoing economic pressures.

2026-07-12 23:51; UTC

Cryptocurrency market shows mixed performance ahead of key U.S. inflation data, as Federal Reserve signals focus on AI in monetary policy.

2026-07-12 23:51; UTC

Cryptocurrency market shows mixed performance ahead of critical U.S. economic data releases that may impact Federal Reserve monetary policy.

2026-07-12 23:51; UTC

Bank of Korea Expected to Maintain Interest Rate at 2.5% Amid Rising Inflation and Economic Uncertainty

2026-07-12 23:51; UTC

China's House Price Index YoY Release on July 15 Expected to Show Continued Decline Amidst Ongoing Property Sector Challenges and Global Economic Uncertainty.

2026-07-12 23:41; UTC

US Import Prices Expected to Decrease by 0.4% Amid Cautious Market Sentiment and Geopolitical Tensions Ahead of Key Economic Data Releases

2026-07-12 23:41; UTC

Housing Starts Data Release on July 17, 2026: Analysts Brace for Weakness Amid High Mortgage Rates and Economic Pressures.

2026-07-12 23:41; UTC

US Export Prices Expected to Rise Amid Inflation Concerns and Geopolitical Tensions Ahead of Key Economic Data Releases

2026-07-12 23:41; UTC

U.S. Building Permits MoM Prel for June 2026 Set to Release Amid Heightened Focus on Housing Trends and Legislative Changes

2026-07-12 23:41; UTC

Upcoming U.S. Housing Starts Data Release on July 17 Expected to Influence Economic Outlook Amid Legislative Changes and Key Macroeconomic Indicators.

2026-07-12 23:41; UTC

U.S. Building Permits Data Release on July 17 Expected to Show Annualized Rate of 1.42 Million Amid Cautious Market Sentiment and Key Macroeconomic Indicators Ahead.

2026-07-12 23:41; UTC

Macro News
Correlated Moves

The US 30Y Treasury Bond Index is lower as capital shifts to technology sectors, with rising oil prices amid U.S.-Iran tensions impacting safe-haven demand.

2026-07-12 23:31; UTC

Australia's NAB Business Confidence Index set for release amid cautious sentiment and global economic uncertainties.

2026-07-12 23:21; UTC

Philadelphia Fed Manufacturing Index Release on July 16 Expected to Show Moderate Optimism Amidst Cautious Market Sentiment and Geopolitical Tensions.

2026-07-12 23:21; UTC

U.S. Retail Sales Expected to Rise 0.3% in June Amid Cautious Optimism and Key Economic Indicators Ahead of Fed Policy Insights

2026-07-12 23:21; UTC

U.S. Retail Sales Ex Autos Expected to Decline 0.1% in June Amid Economic Caution and Geopolitical Tensions

2026-07-12 23:11; UTC

Canada's housing starts data set for July 16, 2026, expected to show resilience with a forecast of 260K units amid positive government initiatives.

2026-07-12 23:01; UTC

NZD/CHF has moved higher in after-market trading, currently 1.22% above its 20-day moving average. No specific news was identified for the price move.

2026-07-12 23:01; UTC

Macro News
Correlated Moves

The U.S. dollar strengthens against major currencies, contributing to a modest after-hours gain in USD/CHF amid rising geopolitical tensions and a higher Dollar Index.

2026-07-12 23:01; UTC

Macro News
Correlated Moves

GBP/USD is trading lower after the U.S. dollar strengthened against major currencies amid geopolitical tensions and anticipation of key macroeconomic data releases.

2026-07-12 23:01; UTC

Macro News

The U.S. dollar rose today, reaching a two-day high against the euro amid geopolitical tensions with Iran affecting shipping route stability.

2026-07-12 23:01; UTC

Market anticipates NY Empire State Manufacturing Index reading of 8.7 amid cautious sentiment ahead of key macroeconomic data releases.

2026-07-12 23:01; UTC

Core PPI for June 2026 set to rise by 0.4% MoM, signaling cautious market sentiment ahead of key economic indicators and Federal Reserve insights.

2026-07-12 23:01; UTC

Market Braces for July 15 PPI Release Amid Anticipated 0.2% Increase and Heightened Volatility from Geopolitical Tensions.

2026-07-12 23:01; UTC

The EUR/HUF is trading higher after-market, reaching a session high earlier. Market focus remains on upcoming U.S. inflation data that may impact Fed policy.

2026-07-12 23:01; UTC

Palladium is trading lower today, continuing a decline since Friday's close. Market focus remains on upcoming U.S. economic data releases.

2026-07-12 23:01; UTC

Macro News
Correlated Moves

Gold prices are lower amid a stronger U.S. dollar and renewed U.S.-Iran military tensions, impacting market sentiment toward safe-haven assets.

2026-07-12 23:01; UTC

EUR/NOK is trading lower in after-market hours, reflecting a decline since Friday's close. The price remains near the midpoint of its one-month range.

2026-07-12 23:01; UTC

Macro News

Copper prices are lower as geopolitical tensions rise amid U.S.-Iran confrontations. Reports of Iraq's oil agreements may further impact market dynamics.

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

101.66% į viršų

12 mėnesių prognozė

Vidutinis 31.6 USD  101.66%

Aukščiausias 40 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

5

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat